Home Cart 0 Sign in  

[ CAS No. 1020149-73-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1020149-73-8
Chemical Structure| 1020149-73-8
Structure of 1020149-73-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1020149-73-8 ]

Related Doc. of [ 1020149-73-8 ]

Alternatived Products of [ 1020149-73-8 ]

Product Details of [ 1020149-73-8 ]

CAS No. :1020149-73-8 MDL No. :MFCD27937047
Formula : C27H23N7O Boiling Point : -
Linear Structure Formula :- InChI Key :QSYLKMKIVWJAAK-UHFFFAOYSA-N
M.W : 461.52 Pubchem ID :24858111
Synonyms :
DNA Methyltransferase Inhibitor II

Calculated chemistry of [ 1020149-73-8 ]

Physicochemical Properties

Num. heavy atoms : 35
Num. arom. heavy atoms : 28
Fraction Csp3 : 0.04
Num. rotatable bonds : 7
Num. H-bond acceptors : 4.0
Num. H-bond donors : 4.0
Molar Refractivity : 140.0
TPSA : 117.85 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -5.72 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.9
Log Po/w (XLOGP3) : 4.78
Log Po/w (WLOGP) : 5.47
Log Po/w (MLOGP) : 2.8
Log Po/w (SILICOS-IT) : 3.29
Consensus Log Po/w : 3.85

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -5.84
Solubility : 0.000663 mg/ml ; 0.00000144 mol/l
Class : Moderately soluble
Log S (Ali) : -6.99
Solubility : 0.0000476 mg/ml ; 0.000000103 mol/l
Class : Poorly soluble
Log S (SILICOS-IT) : -10.5
Solubility : 0.0000000145 mg/ml ; 0.0 mol/l
Class : Insoluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.2

Safety of [ 1020149-73-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1020149-73-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1020149-73-8 ]
  • Downstream synthetic route of [ 1020149-73-8 ]

[ 1020149-73-8 ] Synthesis Path-Upstream   1~10

  • 1
  • [ 20719-43-1 ]
  • [ 133041-90-4 ]
  • [ 1020149-73-8 ]
YieldReaction ConditionsOperation in experiment
59% With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 65℃; for 24 h; Inert atmosphere To a solution of 4-(quinolin-4’-ylamino)benzoic acid 17 (45 mg, 0.17 mmol) and N4-(4’-aminophenyl)-2,4-diamino-6-methylpyrimidine 9 (37 mg, 0.17 mmol) in DMF (1.7 mL) was added N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.06 g, 0.34 mmol) and 1-hydroxybenzotriazole hydrate (0.03 g, 0.17 mmol) and the reaction was stirred for 24 h at 65 ºC. When the reaction was complete the solvent was concentrated in vacuo and the residue was purified by column chromatography (silica gel, 85:13:2 CH2Cl2/MeOH/Et3N) to afford 0.05 g (59percent) of the titled compound as an amorphous yellow solid.
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 701 - 713
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
  • 2
  • [ 611-35-8 ]
  • [ 1020150-22-4 ]
  • [ 1020149-73-8 ]
YieldReaction ConditionsOperation in experiment
0.045 g With palladium diacetate; potassium carbonate; XPhos In water; N,N-dimethyl-formamide; <i>tert</i>-butyl alcohol at 110℃; for 24 h; Sealed tube; Inert atmosphere A sealed tube was charged with Pd(OAc)2 (1 mg, 1.32 mmol) and XPhos (2 mg, 3.97 mmol) and degassed t-BuOH/water (1 mL, 2:1 v/v) was added. The resulting solution was heated for 1 min at 80 ºC and then cannulated into another sealed tube charged with 4-amino-N-[4-(2-amino-6-methylpyrimidine-4-ylamino)phenyl]benzamide 12 (0.07g, 0.20 mmol), 4-chloroquinoline 13 (22.0 mg, 0.13 mmol) and potassium carbonate (0.03 g, 0.18 mmol) in DMF (1 mL). The resulting mixture was stirred for 24 h at 110 ºC. When the reaction was complete the solvent was concentrated in vacuo and the residue was purified by column chromatography (silica gel, 85:13:2 CH2Cl2/MeOH/Et3N) to afford 0.045 g (73percent by 1H-NMR) of the titled compound as an amorphous yellow solid. 1H-NMR (400.13 MHz, DMSO-d6): d 10.22 (s, 1H, CONH), 9.98 (s, 1H, NH), 8.59 (d, J = 5.6 Hz, 1H), 8.48 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.7 Hz, 2H), 8.00-7.94 (m, 2H), 7.86 – 7.75 (m, 3H), 7.74 – 7.61 (m, 4H), 7.57 – 7.50 (m, 3H), 7.44 – 7.37 (m, 1H), 7.15 (d, J = 5.6 Hz, 1H), 6.04 (s, 1H, H5’’), 2.22 (s, 3H, CH3) ppm. 13C-NMR (100.62 MHz, DMSO-d6): d 164.7 (s, CONH), 161.4 (s), 157.1 (s), 154.9 (s), 149.5 (s), 147.8 (d), 145.0 (s), 142.9 (s), 135.4 (s), 134.2 (s), 131.3 (d), 130.2 (s), 129.3 (d, 2x), 125.9 (d, 2x), 123.0 (d, 2x), 121.7 (d), 121.6 (d, 2x), 120.8 (d, 2x), 119.4 (s), 102.5 (d), 96.4 (d), 19.4 (q, CH3)  ppm. HRMS (ESI+): Calcd for C27H24N7O ([M + H]+), 462.20368; found, 462.20330. IR (neat): n 3400-3000 (br, N-H), 2976 (w, C-H), 2891 (w, C-H), 1584 (m), 1510 (m), 1444 (m), 1380 (m), 1318 (m), 1228 (w), 1180 (w), 1095 (w) cm-1. UV (DMSO): lmax 258, 355 nm.
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
  • 3
  • [ 5600-21-5 ]
  • [ 1020149-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[3] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 701 - 713
  • 4
  • [ 100-01-6 ]
  • [ 1020149-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[3] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 701 - 713
  • 5
  • [ 20719-42-0 ]
  • [ 1020149-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[3] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 701 - 713
  • 6
  • [ 611-35-8 ]
  • [ 1020149-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[2] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 701 - 713
  • 7
  • [ 94-09-7 ]
  • [ 1020149-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
[2] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 701 - 713
  • 8
  • [ 1020087-05-1 ]
  • [ 1020149-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
  • 9
  • [ 20719-43-1 ]
  • [ 1020149-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1631 - 1635
  • 10
  • [ 58519-43-0 ]
  • [ 1020149-73-8 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 3, p. 701 - 713
Same Skeleton Products
Historical Records